S.C. MedisProf SRL

The trials here

What the 3 trials at this site are about, from their registry records.

Conditions

• Gastric and oesophageal cancer1 trial
• Lung cancer1 trial
• Metastatic breast cancer1 trial

Phase

• Phase 33 trials

Status

• Active, not recruiting3 trials

Lead sponsor

• Eli Lilly and Company2 trials
• Daiichi Sankyo1 trial

Running trials

• Active, not recruiting

  Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

  NCT04704934· Phase 3· Daiichi Sankyo· Source

• Active, not recruiting

  A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

  NCT02411448· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer

  NCT02107703· Phase 3· Eli Lilly and Company· Source